AESKULISA® tTg ELISA kits perform excellent in Multi-Center Study
The results of a recent Multi-Center Celiac Serology Study undertaken to define the optimal serological screening approach to Celiac Disease clearly showed that dual or combined isotype (IgA+IgG) transglutaminase screening can be advocated as a sensitive and specific alternative to endomysial antibody testing in the assessment of Celiac Disease.AESKULISA® tTg ELISA kits performed excellent. AESKULISA® Celicheck even placed first as the best dual isotype transglutaminase kit of all assays tested.The reason is obvious: AESKULISA® tTg ELISA kits show a unique composition. Human recombinant tissue transglutaminase is cross-linked with gliadin-specific peptides resulting in the creation of neo-epitopes of tTg. The tests are highly specific as no cross-reactions with gliadin occur. Thus the AESKULISA tests are the only available tTg test to mimic the physiologically relevant tTg enzyme complex – offering impressive benefits:
With FDA approval for the improved AESKULISA® tTg IgA and tTg IgG tests for detection of tissue transglutaminase (tTg) antibodies, a new generation of tTg tests for the diagnosis of celiac disease is now at hand for in vitro diagnostic use in the US. AESKULISA® CeliCheck will follow soon.For detailed information about the Multi-Center Coeliac Serology Study “Diagnostic accuracy of celiac serological tests: a prospective study” just send a short E-mail. AESKULISA® Glia-Check, Glia-G and Glia-A for the combined or separate quantitative and qualitative determination of IgG antibodies to alpha gliadin in human serum complete AESKU.DIAGNOSTIC´S portfolio for the diagnosis of celiac disease. | 
